nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00714	0.00714	CcSEcCtD
Lurasidone—Dysuria—Fludarabine—lymphatic system cancer	0.00694	0.00694	CcSEcCtD
Lurasidone—Neutropenia—Fludarabine—lymphatic system cancer	0.00694	0.00694	CcSEcCtD
Lurasidone—Sudden death—Methotrexate—lymphatic system cancer	0.00685	0.00685	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00675	0.00675	CcSEcCtD
Lurasidone—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00669	0.00669	CcSEcCtD
Lurasidone—Renal failure—Fludarabine—lymphatic system cancer	0.0065	0.0065	CcSEcCtD
Lurasidone—Infection—Mechlorethamine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Lurasidone—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Lurasidone—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Lurasidone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Lurasidone—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00632	0.00632	CcSEcCtD
Lurasidone—Arrhythmia—Teniposide—lymphatic system cancer	0.00604	0.00604	CcSEcCtD
Lurasidone—Deep vein thrombosis—Methotrexate—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Lurasidone—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Lurasidone—Anaemia—Teniposide—lymphatic system cancer	0.00544	0.00544	CcSEcCtD
Lurasidone—Agitation—Teniposide—lymphatic system cancer	0.00541	0.00541	CcSEcCtD
Lurasidone—Arrhythmia—Fludarabine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Lurasidone—Leukopenia—Teniposide—lymphatic system cancer	0.00527	0.00527	CcSEcCtD
Lurasidone—Malnutrition—Fludarabine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Lurasidone—Hypertension—Teniposide—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Lurasidone—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Lurasidone—Anaemia—Fludarabine—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Lurasidone—Infection—Teniposide—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Lurasidone—Agitation—Fludarabine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Lurasidone—Dysphagia—Carmustine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Lurasidone—Tachycardia—Teniposide—lymphatic system cancer	0.00469	0.00469	CcSEcCtD
Lurasidone—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Lurasidone—Malaise—Fludarabine—lymphatic system cancer	0.00466	0.00466	CcSEcCtD
Lurasidone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00464	0.00464	CcSEcCtD
Lurasidone—Leukopenia—Fludarabine—lymphatic system cancer	0.00463	0.00463	CcSEcCtD
Lurasidone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Lurasidone—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Lurasidone—Hypotension—Teniposide—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Lurasidone—Convulsion—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Lurasidone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Lurasidone—Neutropenia—Carmustine—lymphatic system cancer	0.00444	0.00444	CcSEcCtD
Lurasidone—Myalgia—Fludarabine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Lurasidone—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Lurasidone—Dyspnoea—Teniposide—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Lurasidone—Dysuria—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Lurasidone—Neutropenia—Vincristine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Lurasidone—Infection—Fludarabine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Lurasidone—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00418	0.00418	CcSEcCtD
Lurasidone—Decreased appetite—Teniposide—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Lurasidone—Renal failure—Carmustine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Lurasidone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Lurasidone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Lurasidone—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Lurasidone—Urinary tract infection—Carmustine—lymphatic system cancer	0.00412	0.00412	CcSEcCtD
Lurasidone—Rash—Mechlorethamine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Lurasidone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Lurasidone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Lurasidone—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Lurasidone—Weight increased—Mitoxantrone—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Lurasidone—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Lurasidone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Lurasidone—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Lurasidone—Renal failure—Mitoxantrone—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Lurasidone—Nausea—Mechlorethamine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Lurasidone—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Lurasidone—Abdominal pain—Teniposide—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Lurasidone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Lurasidone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Lurasidone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Lurasidone—Dysarthria—Methotrexate—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Lurasidone—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Lurasidone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Lurasidone—Fatigue—Fludarabine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Lurasidone—Bradycardia—Mitoxantrone—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Lurasidone—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Lurasidone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Lurasidone—Urethral disorder—Vincristine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Lurasidone—Eye disorder—Carmustine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Lurasidone—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Lurasidone—Anaemia—Bleomycin—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Lurasidone—Asthenia—Teniposide—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Lurasidone—Malaise—Bleomycin—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Lurasidone—Pruritus—Teniposide—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Lurasidone—Arrhythmia—Carmustine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Lurasidone—Leukopenia—Bleomycin—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Lurasidone—Cardiac disorder—Vincristine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Lurasidone—Mental disorder—Carmustine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Lurasidone—Malnutrition—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Lurasidone—Angiopathy—Vincristine—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Lurasidone—Diarrhoea—Teniposide—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Lurasidone—Myalgia—Bleomycin—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Lurasidone—Back pain—Carmustine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Lurasidone—Mental disorder—Vincristine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Lurasidone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Lurasidone—Vision blurred—Carmustine—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Lurasidone—Tremor—Carmustine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Lurasidone—Infection—Bleomycin—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Lurasidone—Anaemia—Carmustine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Lurasidone—Back pain—Vincristine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Lurasidone—Vomiting—Teniposide—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Lurasidone—Agitation—Carmustine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Lurasidone—Asthenia—Fludarabine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Lurasidone—Rash—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Lurasidone—Dermatitis—Teniposide—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Lurasidone—Pruritus—Fludarabine—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Lurasidone—Back pain—Mitoxantrone—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Lurasidone—Leukopenia—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Lurasidone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Lurasidone—Anaemia—Vincristine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Lurasidone—Agitation—Vincristine—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Lurasidone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Lurasidone—Hypotension—Bleomycin—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Lurasidone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Lurasidone—Convulsion—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Lurasidone—Hypertension—Carmustine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Lurasidone—Nausea—Teniposide—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Lurasidone—Anaemia—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Lurasidone—Vertigo—Vincristine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Lurasidone—Leukopenia—Vincristine—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Lurasidone—Myalgia—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Lurasidone—Anxiety—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Lurasidone—Malaise—Mitoxantrone—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Lurasidone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Lurasidone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Lurasidone—Convulsion—Vincristine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Lurasidone—Hypertension—Vincristine—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Lurasidone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Lurasidone—Myalgia—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Lurasidone—Infection—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Lurasidone—Vomiting—Fludarabine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Lurasidone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Lurasidone—Rash—Fludarabine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Lurasidone—Dermatitis—Fludarabine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Lurasidone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Lurasidone—Tachycardia—Carmustine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Lurasidone—Myalgia—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Lurasidone—Anxiety—Mitoxantrone—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Lurasidone—Lethargy—Methotrexate—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Lurasidone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Lurasidone—Infection—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Lurasidone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Lurasidone—Nervous system disorder—Vincristine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Lurasidone—Hypotension—Carmustine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Lurasidone—Nausea—Fludarabine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Lurasidone—Infection—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Lurasidone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Lurasidone—Shock—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Lurasidone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Lurasidone—Insomnia—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Lurasidone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Lurasidone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Lurasidone—Hypotension—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Lurasidone—Dyspnoea—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Lurasidone—Somnolence—Carmustine—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Lurasidone—Decreased appetite—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Lurasidone—Hypotension—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Lurasidone—Insomnia—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Lurasidone—Breast disorder—Methotrexate—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Lurasidone—Decreased appetite—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Lurasidone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Lurasidone—Somnolence—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Lurasidone—Fatigue—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Lurasidone—Asthenia—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Lurasidone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Lurasidone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Lurasidone—Pruritus—Bleomycin—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Lurasidone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Lurasidone—Eosinophilia—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Lurasidone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Lurasidone—Abdominal pain—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Lurasidone—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Lurasidone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Lurasidone—Neutropenia—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Lurasidone—Dysuria—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Lurasidone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Lurasidone—Abdominal pain—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Lurasidone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Lurasidone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Lurasidone—Vomiting—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Lurasidone—Infestation NOS—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Lurasidone—Infestation—Methotrexate—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Lurasidone—Rash—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Lurasidone—Dermatitis—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Lurasidone—Asthenia—Carmustine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Lurasidone—Renal failure—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Lurasidone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Lurasidone—Asthenia—Vincristine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Lurasidone—Diarrhoea—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Lurasidone—Nausea—Bleomycin—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Lurasidone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Lurasidone—Asthenia—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Lurasidone—Dizziness—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Lurasidone—Diarrhoea—Vincristine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Lurasidone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Lurasidone—Urethral disorder—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Lurasidone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Lurasidone—Vomiting—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Lurasidone—Dizziness—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Lurasidone—Rash—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Lurasidone—Dermatitis—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Lurasidone—Eye disorder—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Lurasidone—Vomiting—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Lurasidone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Lurasidone—Rash—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Lurasidone—Dermatitis—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Lurasidone—Nausea—Carmustine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Lurasidone—Angiopathy—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Lurasidone—Vomiting—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Lurasidone—Rash—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Lurasidone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Lurasidone—Mental disorder—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Lurasidone—Malnutrition—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Lurasidone—Nausea—Vincristine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Lurasidone—Nausea—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Lurasidone—Back pain—Methotrexate—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Lurasidone—Vision blurred—Methotrexate—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Lurasidone—Anaemia—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Lurasidone—Malaise—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Lurasidone—Vertigo—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Lurasidone—Leukopenia—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Lurasidone—Convulsion—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Lurasidone—Myalgia—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Lurasidone—Infection—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Lurasidone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Lurasidone—Skin disorder—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Lurasidone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Lurasidone—Hypotension—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Lurasidone—Insomnia—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Lurasidone—Dyspnoea—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Lurasidone—Somnolence—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lurasidone—Dyspepsia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lurasidone—Decreased appetite—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Lurasidone—Fatigue—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Lurasidone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lurasidone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000989	0.000989	CcSEcCtD
Lurasidone—Asthenia—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Lurasidone—Pruritus—Methotrexate—lymphatic system cancer	0.000885	0.000885	CcSEcCtD
Lurasidone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000856	0.000856	CcSEcCtD
Lurasidone—Dizziness—Methotrexate—lymphatic system cancer	0.000827	0.000827	CcSEcCtD
Lurasidone—Vomiting—Methotrexate—lymphatic system cancer	0.000795	0.000795	CcSEcCtD
Lurasidone—Rash—Methotrexate—lymphatic system cancer	0.000789	0.000789	CcSEcCtD
Lurasidone—Dermatitis—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Lurasidone—Nausea—Methotrexate—lymphatic system cancer	0.000743	0.000743	CcSEcCtD
